Purdue Pharma, best known for misleadingly marketing the painkiller OxyContin, received approval for an auto-injector device to reverse opioid overdoses.

This is the second in a periodic series from STAT about how UnitedHealth Group wields its unrivaled physician empire to boost profits and expand its influence.

Pharma leaders have dual missions: advancing health and being responsible to shareholders. They must be held accountable for executing effective strategies for both.

Roche is considering divesting Flatiron Health, highlighting the hazards big pharma can face when buying startups.

Turning powerful gene-editing technologies into broadly useful therapies will require delivery vehicles at once more simple and far more complicated.

Roche abruptly cancelled a trial of a drug for a rare genetic disorder, stunning parents of children enrolled in the study, as well as the academic researchers running it.

Studies being used to decide whether the U.S. should authorize MDMA for traumatized patients missed serious side effects and were marked by bias.

Eli Lilly’s obesity drug Zepbound cut the risk of complications and improved symptoms in patients with a common type of heart failure, the second GLP-1 drug with positive results in…

A new study suggests that an older GLP-1 drug may help protect the brains of people with early Alzheimer’s disease, supporting further research on GLP-1s in neurological diseases.

A half-dozen companies dominate AI scribe contracts with health systems, including Microsoft’s Nuance, Nabla, and Epic-partnered Abridge.

Four pharmaceutical companies involved in the negotiations over prices for Medicare do not expect a significant impact on their businesses after seeing confidential suggested prices.

Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video containing pointed criticism of its new gene therapy for Duchenne muscular dystrophy.

A European Medicines Agency committee that evaluates new drugs recommended that Leqembi, an Alzheimer’s therapy from Eisai and Biogen, should be rejected.

Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster than expected, bringing it closer to joining the highly competitive GLP-1 drug market.

CVS Caremark, one of the largest PBMs, agreed to pay at least $45 million to the state of Illinois to settle allegations that rebates were not passed through.

A U.S. House investigation found PBMs promise to control costs, but have instead steered patients toward higher-priced medicines and affiliated pharmacies — steps that increase spending.

Express Scripts, one of the largest PBMs, overcharged U.S. Postal Service workers by $45 million for prescription drugs during a recent five-year period.

Eli Lilly said its weight loss drug tirzepatide won approval in China, intensifying competition with Novo Nordisk in the key Asian market.

The Broad Data Science Platform's 250 employees are anxious about their future following leadership changes in the division.

Gilead Sciences’ chief medical officer will leave early next year as the drugmaker struggles to find new areas of growth beyond its core HIV medicines

Increasing rigor, and better evidence, can help digital therapeutics companies convince critics that their novel treatments are valuable.

Roche reported positive early data from an obesity drug candidate, bolstering the case it could become a player in the competitive weight loss medicine field.

A Senate bill was touted as a cure for "patent thickets." Some say the drug industry watered it down.

Vertex Pharmaceuticals filed a lawsuit to make it possible to pay for fertility preservation services and treatment for people receiving its Casgevy sickle cell disease therapy.

Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the U.S.

Novo Nordisk's Ozempic was linked to lower rates of dementia and other mental problems in a study that raises expectations about its potential ancillary benefits.

The FDA rejected Novo Nordisk’s weekly insulin for treating diabetes in a rare setback for the company.

Biopharma layoffs have been higher over the past couple of years than during the industry’s boom times amid the pandemic; job cuts this year have mainly hit larger pharmaceutical companies.

Continued growth and investor interest in creating novel neurotherapeutics hinge on their ability to adapt, pivot quickly, and embrace new approaches and development models.